search
Back to results

MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS) (MiECS)

Primary Purpose

Coronary Artery Disease, Aortic Valve Stenosis, Extracorporeal Circulation; Complications

Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Minimal Invasive Extracorporeal Circulation
Conventional cardiopulmonary bypass
Sponsored by
Aristotle University Of Thessaloniki
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease focused on measuring Cardiopulmonary bypass, Extracorporeal circulation, Minimal invasive extracorporeal circulation, Coronary artery bypass grafting, Aortic valve replacement

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients undergoing any elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR surgery using extracorporeal circulation without circulatory arrest.

Exclusion Criteria:

  • Requirement for emergency or salvage operation.
  • Requirement for major aortic surgery (e.g. aortic root replacement).
  • Contraindication or objection (e.g. Jehovah's Witnesses) to transfusion of blood products.
  • Congenital or acquired platelet, red cell or clotting disorders (patients with iron deficient anaemia will not be excluded).
  • Inability to give informed consent for the study (e.g. learning or language difficulties).

Sites / Locations

  • Perfusion Services University Health Network, Toronto General Hospital
  • Department of Cardiothoracic and Vascular Surgery
  • Department of Cardiac Surgery
  • Department of Thoracic and Cardiovascular Surgery, University Medical Centre Goettingen
  • Department of Cardiothoracic and Vascular Surgery, Ulm University Hospital
  • Cardiothoracic Department AHEPA University HospitalRecruiting
  • Department of Cardiac Surgery GVM Anthea Hospital
  • Department of Cardiac Surgery GVM Maria Eleonora Hospital
  • Department of Cardiovascular Surgery, University Hospital Bern
  • Department of Cardiovascular Surgery, Ankara City Hospital
  • Department of Cardiac Surgery, Royal Papworth Hospital
  • Deparment of Cardiac Surgery, Castle Hill Hospital
  • Department of Cardiothoracic Surgery, Hammersmith Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Minimal Invasive Extracorporeal Circulation (MiECC)

Conventional Cardiopulmonary Bypass (cCPB)

Arm Description

Patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), or combined procedure (AVR+CABG) with Minimal Invasive Extracorporeal Circulation (MiECC).

Patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), or combined procedure (AVR+CABG) with conventional cardiopulmonary bypass (cCPB)

Outcomes

Primary Outcome Measures

Composite outcome of postoperative serious adverse events
Incidence of: death, postoperative myocardial infarction according to Fourth Universal Definition of myocardial infarction, stroke, all stage acute kidney injury, as defined with AKI Network criteria, Re-intubation, need for mechanical ventilation for > 48 hours, including multiple episodes when separated by more than 12 hours, reoperation and septicaemia confirmed by positive blood culture.

Secondary Outcome Measures

All-cause mortality
All-cause mortality
New-onset postoperative atrial fibrillation
Incidence of new-onset postoperative atrial fibrillation
Rate of red blood cells transfusion
Units of red blood cells transfused
Rate of platelet transfusion
Units of platelets transfused
Rate of fresh frozen plasma transfusion
Units of fresh frozen plasma transfused
Rate of cryoprecipitate transfusion
Units of cryoprecipitate transfused
Activated Factor VII administration
Incidence of activated factor VII administration
Fibrinogen administration
Incidence of fibrinogen administration
Prothrombin complex concentrate administration
Incidence of prothrombin complex concentrate administration
Time to discharge from cardiac ICU
Time to discharge from cardiac ICU
Time to discharge from hospital
Time to discharge from hospital
Delirium
Incidence of postoperative delirium
Health-Related Quality of Life (HRQoL)
HRQoL assessed with EQ-5D questionnaire

Full Information

First Posted
August 1, 2022
Last Updated
August 4, 2022
Sponsor
Aristotle University Of Thessaloniki
Collaborators
Clinical Research Unit, School of Medicine, Aristotle University of Thessaloniki
search

1. Study Identification

Unique Protocol Identification Number
NCT05487612
Brief Title
MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)
Acronym
MiECS
Official Title
Minimally Invasive Extracorporeal Circulation Versus Conventional Cardiopulmonary Bypass in Patients Undergoing Cardiac Surgery (MiECS): a Randomised Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
May 26, 2022 (Actual)
Primary Completion Date
December 31, 2025 (Anticipated)
Study Completion Date
March 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Aristotle University Of Thessaloniki
Collaborators
Clinical Research Unit, School of Medicine, Aristotle University of Thessaloniki

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
MiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted under the auspices of Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiECC systems in the light of modern perfusion practice worldwide. The primary hypothesis is that MiECC, as compared to conventional CPB (cCPB), reduces the proportion of patients experiencing serious perfusion-related postoperative morbidity after cardiac surgery. The study will be led by the Clinical Research Unit of the Special Unit for Biomedical Research and Education (SUBRE), Aristotle University of Thessaloniki School of Medicine in Greece (AUSoM) with Chief Investigator Professor Kyriakos Anastasiadis, who is a key-opinion-leader in the field of MiECC, founder and Executive Board of MiECTiS.
Detailed Description
Despite a fall in mortality rates over the past decade, patients having cardiac surgery continue to experience serious postoperative complications. The risk of serious and relatively common surgical complications is often a consequence of stopping the heart during the operation, using the heart and lung machine (conventional cardiopulmonary bypass; cCPB), and restarting and reperfusing the heart at the end of the operation. Although several strategies have been developed to reduce such complications, they still occur and can be life threatening; they also increase the length of time a patient spends in the hospital. Miniaturised heart lung machines (minimally invasive extracorporeal circulation; MiECC) have been developed with the aim of reducing the number of postoperative complications arising from using cCPB. Because of the variety of miniaturised systems that have been evaluated, the different types of patients and outcomes investigated, and the poor quality of previous studies, the effectiveness of MiECC in reducing postoperative complications has not been established and most hospitals continue to use cCPB. Our primary hypothesis is that, compared to cCPB, using a MiECC system during cardiac surgery reduces the proportion of patients having one of several serious postoperative complications (death, myocardial infarction, stroke, acute kidney injury, reintubation, tracheostomy, mechanical ventilation for more than 48 hours, or reoperation) up to 30 days after surgery. In addition, the investigators hypothesise that MiECC reduces the amount of blood products transfused, time to discharge from the cardiac intensive care unit and hospital and the health care resources used during the hospital stay. Study investigators propose to carry out a large, multicentre randomised controlled trial in 10 to 15 cardiac surgery centres worldwide. Patients will be eligible if they are having coronary artery bypass surgery, aortic valve replace or both using a heart lung machine without circulatory arrest. Centres may recruit patients having all, or a subset of, operation types. It is expected that 20 % to 23% of patients will experience one or more of the serious complications (the primary outcome). In order to be able confidently to detect a 30% relative reduction in the risk of this outcome, the investigators plan to recruit 1,300 participants across all sites.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease, Aortic Valve Stenosis, Extracorporeal Circulation; Complications
Keywords
Cardiopulmonary bypass, Extracorporeal circulation, Minimal invasive extracorporeal circulation, Coronary artery bypass grafting, Aortic valve replacement

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Patients undergoing elective or urgent coronary artery bypass grafting, aortic valve replacement or both procedures CABG+AVR using extracorporeal circulation without circulatory arrest will be randomised (1:1 ratio) to having surgery using Minimal Invasive Extracorporeal Circulation (MiECC) or conventional cardiopulmonary bypass (cCPB).
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
1300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Minimal Invasive Extracorporeal Circulation (MiECC)
Arm Type
Active Comparator
Arm Description
Patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), or combined procedure (AVR+CABG) with Minimal Invasive Extracorporeal Circulation (MiECC).
Arm Title
Conventional Cardiopulmonary Bypass (cCPB)
Arm Type
Active Comparator
Arm Description
Patients undergoing coronary artery bypass grafting (CABG), aortic valve replacement (AVR), or combined procedure (AVR+CABG) with conventional cardiopulmonary bypass (cCPB)
Intervention Type
Device
Intervention Name(s)
Minimal Invasive Extracorporeal Circulation
Intervention Description
Cardiac surgery with Minimal Invasive Extracorporeal Circulation (MiECC).
Intervention Type
Device
Intervention Name(s)
Conventional cardiopulmonary bypass
Intervention Description
Cardiac surgery with conventional cardiopulmonary bypass (cCPB).
Primary Outcome Measure Information:
Title
Composite outcome of postoperative serious adverse events
Description
Incidence of: death, postoperative myocardial infarction according to Fourth Universal Definition of myocardial infarction, stroke, all stage acute kidney injury, as defined with AKI Network criteria, Re-intubation, need for mechanical ventilation for > 48 hours, including multiple episodes when separated by more than 12 hours, reoperation and septicaemia confirmed by positive blood culture.
Time Frame
30 days after randomization following the index admission
Secondary Outcome Measure Information:
Title
All-cause mortality
Description
All-cause mortality
Time Frame
30 days after randomization following the index admission
Title
New-onset postoperative atrial fibrillation
Description
Incidence of new-onset postoperative atrial fibrillation
Time Frame
Through initial hospital admission from surgery to initial discharge from hospital, an average of 1 week.
Title
Rate of red blood cells transfusion
Description
Units of red blood cells transfused
Time Frame
30 days after randomization following the index admission
Title
Rate of platelet transfusion
Description
Units of platelets transfused
Time Frame
30 days after randomization following the index admission
Title
Rate of fresh frozen plasma transfusion
Description
Units of fresh frozen plasma transfused
Time Frame
30 days after randomization following the index admission
Title
Rate of cryoprecipitate transfusion
Description
Units of cryoprecipitate transfused
Time Frame
30 days after randomization following the index admission
Title
Activated Factor VII administration
Description
Incidence of activated factor VII administration
Time Frame
30 days after randomization following the index admission
Title
Fibrinogen administration
Description
Incidence of fibrinogen administration
Time Frame
30 days after randomization following the index admission
Title
Prothrombin complex concentrate administration
Description
Incidence of prothrombin complex concentrate administration
Time Frame
30 days after randomization following the index admission
Title
Time to discharge from cardiac ICU
Description
Time to discharge from cardiac ICU
Time Frame
Through initial hospital admission from surgery to initial discharge from hospital, an average of 1 week.
Title
Time to discharge from hospital
Description
Time to discharge from hospital
Time Frame
Through initial hospital admission from surgery to initial discharge from hospital, an average of 1 week.
Title
Delirium
Description
Incidence of postoperative delirium
Time Frame
Up to 5 days postoperatively
Title
Health-Related Quality of Life (HRQoL)
Description
HRQoL assessed with EQ-5D questionnaire
Time Frame
90 days after randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients undergoing any elective or urgent coronary artery bypass grafting (CABG), aortic valve replacement (AVR) or CABG+AVR surgery using extracorporeal circulation without circulatory arrest. Exclusion Criteria: Requirement for emergency or salvage operation. Requirement for major aortic surgery (e.g. aortic root replacement). Contraindication or objection (e.g. Jehovah's Witnesses) to transfusion of blood products. Congenital or acquired platelet, red cell or clotting disorders (patients with iron deficient anaemia will not be excluded). Inability to give informed consent for the study (e.g. learning or language difficulties).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Georgios Papazisis, Assoc. Prof.
Phone
+30 2310999323
Email
papazisg@auth.gr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Kyriakos Anastasiadis, Professor
Organizational Affiliation
Aristotle University Of Thessaloniki, School of Medicine
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Polychronis Antonitsis, Assoc. Prof.
Organizational Affiliation
Aristotle University Of Thessaloniki, School of Medicine
Official's Role
Study Director
Facility Information:
Facility Name
Perfusion Services University Health Network, Toronto General Hospital
City
Toronto
ZIP/Postal Code
M5G 2C4
Country
Canada
Individual Site Status
Active, not recruiting
Facility Name
Department of Cardiothoracic and Vascular Surgery
City
Braunschweig
ZIP/Postal Code
38126
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Department of Cardiac Surgery
City
Coswig
ZIP/Postal Code
06869
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Department of Thoracic and Cardiovascular Surgery, University Medical Centre Goettingen
City
Göttingen
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Department of Cardiothoracic and Vascular Surgery, Ulm University Hospital
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Individual Site Status
Active, not recruiting
Facility Name
Cardiothoracic Department AHEPA University Hospital
City
Thessaloníki
ZIP/Postal Code
54636
Country
Greece
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Polychronis Antonitsis, Assoc. Prof.
Phone
+30 2310994871
Email
antonits@auth.gr
Facility Name
Department of Cardiac Surgery GVM Anthea Hospital
City
Bari
ZIP/Postal Code
70124
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Department of Cardiac Surgery GVM Maria Eleonora Hospital
City
Palermo
ZIP/Postal Code
90135
Country
Italy
Individual Site Status
Active, not recruiting
Facility Name
Department of Cardiovascular Surgery, University Hospital Bern
City
Bern
ZIP/Postal Code
CH-3010
Country
Switzerland
Individual Site Status
Active, not recruiting
Facility Name
Department of Cardiovascular Surgery, Ankara City Hospital
City
Ankara
Country
Turkey
Individual Site Status
Active, not recruiting
Facility Name
Department of Cardiac Surgery, Royal Papworth Hospital
City
Cambridge
ZIP/Postal Code
CB2 0AY
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Deparment of Cardiac Surgery, Castle Hill Hospital
City
Hull
ZIP/Postal Code
HU16 5JQ
Country
United Kingdom
Individual Site Status
Active, not recruiting
Facility Name
Department of Cardiothoracic Surgery, Hammersmith Hospital
City
London
ZIP/Postal Code
W120HS
Country
United Kingdom
Individual Site Status
Active, not recruiting

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
26819269
Citation
Anastasiadis K, Murkin J, Antonitsis P, Bauer A, Ranucci M, Gygax E, Schaarschmidt J, Fromes Y, Philipp A, Eberle B, Punjabi P, Argiriadou H, Kadner A, Jenni H, Albrecht G, van Boven W, Liebold A, de Somer F, Hausmann H, Deliopoulos A, El-Essawi A, Mazzei V, Biancari F, Fernandez A, Weerwind P, Puehler T, Serrick C, Waanders F, Gunaydin S, Ohri S, Gummert J, Angelini G, Falk V, Carrel T. Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, definitions and potential benefits. A position paper from the Minimal invasive Extra-Corporeal Technologies international Society (MiECTiS). Interact Cardiovasc Thorac Surg. 2016 May;22(5):647-62. doi: 10.1093/icvts/ivv380. Epub 2016 Jan 26.
Results Reference
background
PubMed Identifier
34137323
Citation
Anastasiadis K, Antonitsis P, Asteriou C, Deliopoulos A, Argiriadou H. Modular minimally invasive extracorporeal circulation ensures perfusion safety and technical feasibility in cardiac surgery; a systematic review of the literature. Perfusion. 2022 Nov;37(8):852-862. doi: 10.1177/02676591211026514. Epub 2021 Jun 17.
Results Reference
background
PubMed Identifier
32781894
Citation
COMICS investigators, The COMICS investigators. Conventional versus minimally invasive extracorporeal circulation in patients undergoing cardiac surgery: protocol for a randomised controlled trial (COMICS). Perfusion. 2021 May;36(4):388-394. doi: 10.1177/0267659120946731. Epub 2020 Aug 12.
Results Reference
background
PubMed Identifier
31576396
Citation
Wahba A, Milojevic M, Boer C, De Somer FMJJ, Gudbjartsson T, van den Goor J, Jones TJ, Lomivorotov V, Merkle F, Ranucci M, Kunst G, Puis L; EACTS/EACTA/EBCP Committee Reviewers. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardiothorac Surg. 2020 Feb 1;57(2):210-251. doi: 10.1093/ejcts/ezz267. No abstract available.
Results Reference
background
PubMed Identifier
29778331
Citation
Ranucci M, Johnson I, Willcox T, Baker RA, Boer C, Baumann A, Justison GA, de Somer F, Exton P, Agarwal S, Parke R, Newland RF, Haumann RG, Buchwald D, Weitzel N, Venkateswaran R, Ambrogi F, Pistuddi V. Goal-directed perfusion to reduce acute kidney injury: A randomized trial. J Thorac Cardiovasc Surg. 2018 Nov;156(5):1918-1927.e2. doi: 10.1016/j.jtcvs.2018.04.045. Epub 2018 Apr 18.
Results Reference
background
PubMed Identifier
31293801
Citation
Anastasiadis K, Argiriadou H, Deliopoulos A, Antonitsis P. Minimal invasive extracorporeal circulation (MiECC): the state-of-the-art in perfusion. J Thorac Dis. 2019 Jun;11(Suppl 10):S1507-S1514. doi: 10.21037/jtd.2019.01.66. No abstract available.
Results Reference
background
PubMed Identifier
26537755
Citation
Kowalewski M, Pawliszak W, Raffa GM, Malvindi PG, Kowalkowska ME, Zaborowska K, Kowalewski J, Tarelli G, Taggart DP, Anisimowicz L. Safety and efficacy of miniaturized extracorporeal circulation when compared with off-pump and conventional coronary artery bypass grafting: evidence synthesis from a comprehensive Bayesian-framework network meta-analysis of 134 randomized controlled trials involving 22 778 patients. Eur J Cardiothorac Surg. 2016 May;49(5):1428-40. doi: 10.1093/ejcts/ezv387. Epub 2015 Nov 3.
Results Reference
background
Links:
URL
https://miectis.e-dendrite.com
Description
MiECS Clinical Trial Registry by Dendrite

Learn more about this trial

MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)

We'll reach out to this number within 24 hrs